Biotechnology

Compass Therapeutics

Compass Therapeutics released FY2026 Q1 earnings on May 5 (EST), actual revenue USD 0 (forecast USD -642.86 K), actual EPS USD -0.1 (forecast USD -0.0986)

Compass Therapeutics posts Q1 net loss and plans to hold FDA meeting

HC Wainwright Analysts Forecast Compass Therapeutics EPS for 2026

Compass Therapeutics released FY2025 earnings on March 5, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4216 (forecast USD -0.4218)

Compass Therapeutics released FY2025 Q4 earnings on March 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.085 (forecast USD -0.09)

Compass Therapeutics Inc. Reports Clinical Progress and Leadership Appointments

William Blair Begins Coverage of Compass Therapeutics, Highlights tovecimig Potential

Compass Therapeutics Receives 'Moderate Buy' Consensus Rating from Analysts

Compass Therapeutics Announces Participation in Investor Events

Compass Therapeutics released FY2025 9 Months Earnings on November 5, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.3485

Compass Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0844 (forecast USD -0.139)

Charles Zhu Gives Compass Therapeutics a Buy Rating

Guggenheim Raises Compass Price Target

Compass Therapeutics released FY2025 Semi-Annual earnings on August 11, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.264 (forecast USD -0.23)

Compass Therapeutics released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1437 (forecast USD -0.124)

Compass Therapeutics Inc. expects to report a loss of 12 cents per share for Q2 2025

Compass Therapeutics Inc. CEO Acquires Company Shares

Compass Therapeutics EPS in line with expectations

Compass Therapeutics Reports Widening Quarterly Loss

Guggenheim Downgrades Compass Therapeutics Target Price

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

CMPX

Analyst Charles Zhu from LifeSci Capital has reiterated a Buy rating on Compass Therapeutics, maintaining a price target of $6.00. This decision is based on the company's clinical progress and regulatory outlook, particularly the COMPANION-002 results, which enhance approval odds. Upcoming catalysts and a solid cash runway further support this rating. H.C. Wainwright also reaffirmed a Buy rating with a higher price target of $24.00.

Tip Ranks

Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained

Compass Therapeutics, Inc. reported its 1Q 2026 results, showing a revenue of $18.76M and a net loss of $18.32M, reflecting a year-over-year increase in losses. The company achieved a clinical milestone with its lead candidate, Tovecimig, in a biliary tract cancer study and received FDA Orphan Drug Designation. The financial position remains strong, with cash expected to support operations until 2028, despite a 41% rise in G&A expenses. The company is advancing multiple antibody programs and preparing for regulatory engagement.

TradingView

Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary

Earnings Watch

Compass Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Compass Therapeutics fell 9.51%; KalVista Pharmaceuticals rose 38.75%, with a transaction volume of USD 1.509 billion; AbbVie rose 3.50%, with a transaction volume of USD 1.433 billion; Regeneron Pharmaceuticals fell 7.24%, with a transaction volume of USD 829 million; Amgen fell 0.46%, with a market value of USD 182.4 billion

Price Alert

KalVista Pharma

Abbvie

Regeneron Pharma

Amgen

U.S. stock market update: Compass Therapeutics down 9.51%, concerns in the market triggered by failed cancer trials and target price downgrade

Compass Therapeutics (NASDAQ:CMPX) shares hit a new 52-week low of $1.61, closing at $1.79 with significant trading volume. Analysts have mixed ratings: HC Wainwright maintains a "buy" with a $24 target, while Wall Street Zen downgraded to "sell." The stock has a market cap of $322.36 million and a PE ratio of -4.16. Institutional investors hold 68.43% of shares. The company focuses on immuno-oncology therapies and reported an EPS of ($0.09), slightly above estimates. Analysts forecast a Moderate Buy rating with an average price target of $14.20.

Market Beat

Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month Low  - What's Next?

ADGM

SCNI

MANE

EDSA

SGMT

ADTX

On Monday, several health care stocks experienced significant movements. Gainers included Sagimet Biosciences (SGMT) with a 46.6% increase to $8.59, Edesa Biotech (EDSA) up 42.81% to $10.37, and Veradermics (MANE) rising 36.02% to $92.28. Conversely, Compass Therapeutics (CMPX) saw a sharp decline of 62.7% to $1.88, while Adagio Medical Holdings (ADGM) fell 27.83% to $1.09. Other notable losers included Aditxt (ADTX) down 22.83% and Scinai Immunotherapeutics (SCNI) down 18.62%.

benzinga_article

Adagio Medical

Scinai Immunotherapeutics

VeraDermics

Edesa Biotech

Sagimet Biosciences

Aditxt

iShares Biotechnology ETF

Onconetix

Aspire Biopharma

Absci

Silo Pharma

Virax Biolabs

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)

12 Health Care Stocks Moving In Monday's Intraday Session

H.C. Wainwright analyst Joseph Pantginis has reiterated a Buy rating on CMPX stock, maintaining a $24 price target. He cites the strength of tovecimig’s progression-free survival data in biliary tract cancer as a key factor, suggesting the market undervalues its clinical benefits. Pantginis views recent share weakness as due to regulatory uncertainty rather than drug failure, and anticipates a successful FDA dialogue and potential U.S. approval in 2027.

- Analyst Joseph Pantginis from H.C. Wainwright reaffirmed a bullish outlook on CMPX stock with a buy rating, citing several factors.  
- He highlighted the strong performance of tovecimig in clinical data for second-line cholangiocarcinoma, noting a significant extension of patient survival compared to standard chemotherapy.  
- Pantginis views recent stock price weakness as driven by regulatory uncertainty rather than drug failure, maintaining a target price of $24 based on potential FDA dialogue and a planned 2026 BLA submission.

Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged

Compass Therapeutics Inc. (NASDAQ:CMPX) shares plummeted 60% after the company reported that its drug tovecimig did not meet the overall survival endpoint in a biliary tract cancer study due to significant crossover from the control group. While the overall survival was 8.9 months for the combination therapy versus 9.4 months for the control, tovecimig showed a statistically significant improvement in progression-free survival (PFS) of 4.7 months compared to 2.6 months for paclitaxel alone. The company plans to discuss these findings with the FDA ahead of a Biologics License Application submission.

Shutterstock

Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients

Compass Therapeutics(CMPX.US)